Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$100.00K$100.00Kderivedno prior Q4 2022 on file Net Income-$573.55K-$573.55KderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$161,498N/M Operating Cash Flowderived$20,517N/M Margins · derivedOperating margin-161.5%
Net margin-573.6%
ended Aug 31, 2023 · filed Nov 30, 2023 · 91 d after period end